(Q35062386)

6 August 2017

1 reference

title

HDL in risk prediction and its direct and indirect involvement in atherogenesis (English)

1 reference

6 August 2017

Paul Durrington

1

1 reference

6 August 2017

publication date

1 December 2002

1 reference

Atherosclerosis. Supplements

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

3-12

1 reference

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The rediscovery of high density lipoprotein: a negative risk factor in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The proving of the lipid hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Assessing possible hazards of reducing serum cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Cholesterol reduction yields clinical benefit. A new look at old data

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Debate: at what level of coronary heart disease risk should a statin be prescribed?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Cost-effectiveness of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Cardiovascular disease risk profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Calculation of coronary risk in Type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Methods for the prediction of coronary heart disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Lipid-lowering for prevention of coronary heart disease: what policy now?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Comparative accuracy of cardiovascular risk prediction methods in primary care patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Plasma lipid transfer proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

What do all the apolipoprotein E receptors do?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Fetal and maternal lipoprotein metabolism in human pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

An investigation of the role of lecithin: cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of pre-beta high density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Paraoxonase and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

The effects of altered apolipoprotein A-I structure on plasma HDL concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in Rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Plasma Lipids and Lipoproteins in Vegetarians and Controls

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Plasma apoprotein and lipoprotein lipid levels in vegetarians

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

Increase of serum high-density lipoprotein in phenytoin users

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2802%2900042-9

7 January 2021

10.1016/S1567-5688(02)00042-9

Identifiers

DOI

1 reference

6 August 2017

1 reference